GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
Novo Nordisk AS Class B NONOF
News
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
European Pharma Leaders Push for National Reforms to Boost Investment
Novo Nordisk's stock tumbles as doubts persist about Ozempic maker's strategy
Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years — Update
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years
Novo Gets EU Regulator Backing to Expand Label of Growth-Hormone Treatment
Novo Gets EU Drug Regulator Backing for Hemophilia Drug
Novo Partners With Anthropic to Speed Up Drug Discovery Using Claude
Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars
Novo Nordisk Slims Name Down to Novo — Update
Novo Nordisk to Rebrand as Novo
United States